Latest News
We have received excellent information about COVID-19 for women with breast cancer from the Māori Cancer Leadership Group and the Cancer Control Agency, that you will find attached.
BCAC is thrilled that Aotearoa New Zealand has acted so decisively and early in a bid to contain and control COVID-19 (coronavirus). There are sensible rules in place which give our country an opportunity to lead the world in effective management of this deadly virus.
As New Zealand moves to halt the spread of the new flu-like virus COVID-19 (Coronavirus), we have pulled together this information for New Zealanders with breast cancer and their families and whānau. This virus can affect lungs and airways, and has been declared a pandemic by the World Health Organisation.
BCAC media release - 5 March 2020
It is fantastic news that funding for a vital drug for women with advanced breast cancer, palbociclib (Ibrance), will cover the costs for all those who need it , Libby Burgess, Chair of the Breast Cancer Aotearoa Coalition (BCAC) says.
A clinical trial shows that tucatinib, an investigative therapy used in combination with trastuzumab and capecitabine, reduces risk of death at two years by one-third in women with HER2-positive metastatic breast cancer (HER2+ MBC).
BCAC media release, 15 January 2020: Breast Cancer Aotearoa Coalition (BCAC) is delighted to hear that Ibrance (palbociclib) will be funded by PHARMAC from 1 April 2020.
BCAC would love you to show support for an intrepid couple who cycled from Dunedin to Parliament to garner support for a petition that would help improve the lives of women with breast cancer and people with other diseases.
Advocates are always a big part of the San Antonio Breast Cancer Symposium, with wonderful opportunities to share ideas, experience, priorities and plans. This photo shows patient advocates together in Texas. The photo is courtesy of the Alamo Breast Cancer Foundation, which we are very pleased sponsored our Deputy Chair Emma Crowley to attend the Symposium.
BCAC Secretary Fay Sowerby says a presentation on proteomics was one of the highlights of the San Antonio Breast Cancer Symposium. Tao Liu, from Pacific Western University described advanced enabling technologies for cancer proteomics developed to be efficient and replicable to handle bulk proteomics workflow typically handling 10,000 proteins and greater...
Initial trial results on the cost and effectiveness of MRI breast cancer screening compared to mammography, in women with a familial risk, have been presented at the San Antonio Breast Cancer Symposium. The FaMRIsc study is the first randomised trial that has made this comparison.
